Your browser doesn't support javascript.
loading
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.
Williams, Thomas; John, Nevin; Calvi, Alberto; Bianchi, Alessia; De Angelis, Floriana; Doshi, Anisha; Wright, Sarah; Shatila, Madiha; Yiannakas, Marios C; Chowdhury, Fatima; Stutters, Jon; Ricciardi, Antonio; Prados, Ferran; MacManus, David; Braisher, Marie; Blackstone, James; Ciccarelli, Olga; Gandini Wheeler-Kingshott, Claudia A M; Barkhof, Frederik; Chataway, Jeremy.
Affiliation
  • Williams T; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • John N; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Calvi A; Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
  • Bianchi A; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • De Angelis F; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Doshi A; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Wright S; National Institute for Health Research, Biomedical Research Centre, University College London Hospitals, London, UK.
  • Shatila M; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Yiannakas MC; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Chowdhury F; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Stutters J; NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Ricciardi A; NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Prados F; NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • MacManus D; NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Braisher M; NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Blackstone J; Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK.
  • Ciccarelli O; Universitat Oberta de Catalunya, Barcelona, Spain.
  • Gandini Wheeler-Kingshott CAM; NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Barkhof F; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Chataway J; Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Eur J Neurol ; 30(9): 2769-2780, 2023 09.
Article in En | MEDLINE | ID: mdl-37318885
BACKGROUND AND PURPOSE: There is increasing evidence that cardiovascular risk (CVR) contributes to disability progression in multiple sclerosis (MS). CVR is particularly prevalent in secondary progressive MS (SPMS) and can be quantified through validated composite CVR scores. The aim was to examine the cross-sectional relationships between excess modifiable CVR, whole and regional brain atrophy on magnetic resonance imaging, and disability in patients with SPMS. METHODS: Participants had SPMS, and data were collected at enrolment into the MS-STAT2 trial. Composite CVR scores were calculated using the QRISK3 software. Prematurely achieved CVR due to modifiable risk factors was expressed as QRISK3 premature CVR, derived through reference to the normative QRISK3 dataset and expressed in years. Associations were determined with multiple linear regressions. RESULTS: For the 218 participants, mean age was 54 years and median Expanded Disability Status Scale was 6.0. Each additional year of prematurely achieved CVR was associated with a 2.7 mL (beta coefficient; 95% confidence interval 0.8-4.7; p = 0.006) smaller normalized whole brain volume. The strongest relationship was seen for the cortical grey matter (beta coefficient 1.6 mL per year; 95% confidence interval 0.5-2.7; p = 0.003), and associations were also found with poorer verbal working memory performance. Body mass index demonstrated the strongest relationships with normalized brain volumes, whilst serum lipid ratios demonstrated strong relationships with verbal and visuospatial working memory performance. CONCLUSIONS: Prematurely achieved CVR is associated with lower normalized brain volumes in SPMS. Future longitudinal analyses of this clinical trial dataset will be important to determine whether CVR predicts future disease worsening.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Cardiovascular Diseases / Multiple Sclerosis, Chronic Progressive / Multiple Sclerosis Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Eur J Neurol Journal subject: NEUROLOGIA Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Cardiovascular Diseases / Multiple Sclerosis, Chronic Progressive / Multiple Sclerosis Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Eur J Neurol Journal subject: NEUROLOGIA Year: 2023 Type: Article